TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse modelSebastian Johannes Schober, Uwe Thiel|Frontiers in Immunology|2024Cited by 5
YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cellsAnna Josefine von Ofen, Sebastian Johannes Schober|Frontiers in Oncology|2024Cited by 1